Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers

Fiocco, Ugo; Sfriso, Paolo; Oliviero, Francesca; Lunardi, Francesca; Calabrese, Fiorella; Scagliori, Elena; Cozzi, L.; Maggio, Antonio Di; Nardacchione, Roberto; Molena, Béatrice; Felicetti, Mara; Gazzola, Katia; Stramare, Roberto; Rubaltelli, Léopoldo; Accordi, Benedetta; Costa, Luisa; Roux‐Lombard, Pascale; Punzi, Leonardo; Dayer, Jean‐Michel

doi:10.1016/j.jbspin.2012.06.016

Cited by 35 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those authors reported a reduction in both synovial thickening and power Doppler flow in parallel to a reduction of clinical and laboratory signs of disease activity [40]. Another study has showed an improvement either in local and systemic clinical scores or in synovial thickness measures by C-MR and US in peripheral spondyloarthritis patients following intra-articular TNF-α blocking that was shown in an open-label study [41]. The US response of the skin and joints after infliximab treatment was examined in a multicenter study that reported an improvement in synovitis and power Doppler signal concomitant with improvement of dermal lesions at 24 weeks [42].…”

Section: Discussionmentioning

confidence: 93%

Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate

et al. 2014

View full text Add to dashboard Cite

The objective of the study was to combine ultrasonographic (US) with clinical findings for comparing the effect of adalimumab (ADA) to methotrexate (MTX) on the thickness of tendons and enthesis in psoriatic arthritis (PsA) patients. Forty-three consecutive PsA patients were examined at baseline and after 6 and 12 weeks of treatment with ADA or MTX. The US assessment included thickness measurement of the extensor (ET) and flexor tendons (FT) of the second and third finger of both hands, plantar aponeurosis (PA) and the Achilles tendon (AT) bilaterally. Disease activity (DA) was assessed by the number of tender (TJ) and swollen joints (SJ), the number of inflamed enthesis (IE), pain assessment (PAI), and patient (PDAI) and physician (PHDAI) disease activity evaluations by visual activity score (VAS). Nineteen patients received MTX and 24 patients received ADA. All DA parameters improved in both groups. A decrease in thickness of tendons and enthesis was observed only in the ADA group, reaching a level of significance for the left AT (p = 0.01), left PA (p = 0.007), the second left FT (p = 0.04) and the third ET (p = 0.04). ADA patients showed a trend towards a better response to treatment compared to MTX patients that reach significance at week 6 of treatment for the thickness of left AT (p = 0.04), left PA (p = 0.03), the number of TJ (p = 0.0136), PAI (p = 0.0028), and PDAI (p = 0.029). ADA treatment for PsA compared to MTX significantly improved signs of DA and several US parameters. US assessment of enthesis can be an additional useful tool in the monitoring of psoriatic enthesopathy.

show abstract

Section: Discussionmentioning

confidence: 93%

Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate

et al. 2014

View full text Add to dashboard Cite

show abstract

“…well-controlled by non-steroid anti-inflammatory drugs or antitumor necrosis factor-␣ (anti-TNF-␣) agent [19,20]. The important role of Tregs in the maintenance of immune tolerance has prompted us to hypothesize that an alteration in the Tregs quantity may contribute to the development and disease maintenance of the human auto-inflammatory diseases such as AS.…”

Section: Introductionmentioning

confidence: 99%

Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

et al. 2015

View full text Add to dashboard Cite

“…SpA therapy has been revolutionized by increasing knowledge of the pathogenetic mechanisms of the disease, involving dysfunction and oversecretion of multiple proinflammatory molecules, in particular tumor necrosis factor- (TNF-) α [11–13]. …”

Section: Introductionmentioning

confidence: 99%

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-αAgents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice

Fabbroni

Cantarini

Caso

et al. 2014

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Objective. The study aim was to determine treatment persistence rates and to identify causes of discontinuation in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients in clinical practice. Methods. Patients treated with adalimumab (ADA), etanercept (ETA), or infliximab (INF) were retrospectively included. Treatment persistence rates were analyzed by means of a stepwise logistic regression. Differences between therapy duration were assessed by means of an analysis of variance model (ANOVA), while a chi-square test was used to evaluate relationships between therapies and causes of treatment discontinuation and the administration of concomitant disease-modifying antirheumatic drugs (DMARDs) among therapies and types of disease considering completed courses of therapy versus courses that were discontinued. Results. 268 patients received a total of 353 anti-TNF treatment courses (97 ADA, 180 ETA, and 76 INF). Comparison among therapies showed significant difference regarding the treatment persistence rates due to the contrast between ETA and INF (P = 0.0062). We observed that 84.7% of patients were still responding after 6 months of follow-up. Comparison among diseases showed that there were significant differences between PsA and AS (P = 0.0073) and PsA and PsA with predominant axial involvement (P = 0.0467) in terms of duration of the therapy, while there were no significant differences with regard to the persistence rate. Conclusions. In this cohort, anti-TNF-α therapy was associated with high drug persistence rates. As in rheumatoid arthritis, switching to another anti-TNF-α agent can be an effective option when, during the treatment of AS or PsA, therapy is suspended because of inefficacy or an adverse event. Combination therapy with DMARDs was associated with a better persistence rate.

show abstract

Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers

Cited by 35 publications

References 34 publications

Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate

Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate

Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-αAgents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice

Contact Info

Product

Resources

About